Pallas Capital Advisors LLC Acquires 4,110 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Pallas Capital Advisors LLC grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 270.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,629 shares of the medical research company's stock after acquiring an additional 4,110 shares during the quarter. Pallas Capital Advisors LLC's holdings in IQVIA were worth $992,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in IQV. Hickory Asset Management Inc. bought a new position in shares of IQVIA during the 4th quarter worth approximately $941,000. Compound Global Advisors LLC purchased a new stake in shares of IQVIA during the 4th quarter valued at $334,000. Empowered Funds LLC boosted its stake in IQVIA by 40.0% in the fourth quarter. Empowered Funds LLC now owns 4,813 shares of the medical research company's stock valued at $946,000 after acquiring an additional 1,376 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in IQVIA in the fourth quarter worth $60,000. Finally, Bruni J V & Co. Co. bought a new stake in shares of IQVIA in the fourth quarter valued at $13,304,000. Institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

NYSE IQV traded down $2.48 on Friday, reaching $156.65. 1,473,864 shares of the company's stock traded hands, compared to its average volume of 1,619,178. The stock has a market cap of $27.10 billion, a PE ratio of 20.89, a P/E/G ratio of 1.99 and a beta of 1.28. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The stock has a 50-day simple moving average of $147.59 and a 200 day simple moving average of $177.68.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same quarter last year, the firm earned $2.54 EPS. The firm's quarterly revenue was up 2.5% compared to the same quarter last year. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Mizuho decreased their price objective on IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a report on Thursday, May 15th. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and lowered their price target for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Truist Financial reduced their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. Robert W. Baird dropped their target price on IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Finally, Barclays reduced their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a report on Wednesday, May 7th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.